When:   Upcoming program dates to be announced soon
Where:  Harvard Medical School  |  Boston
What:    2-day program for science and business leaders involved in drug development 
*Discount available for groups of three or more from a single organization

There has been increasing interest and investment in applying genomics and related technologies to drug discovery and development. However, with the exception of a small number of well-known successes, much uncertainty remains about how to best leverage these tools throughout the pharmaceutical value chain.

Led by renowned leaders from industry and academia, this program provides a unique opportunity to delve into the use of genomics in rare and complex diseases, and throughout the drug discovery, development, regulatory, and post-regulatory phases. Pre-work, case-based teaching, and project work will ground insights in real-world applications. 

Program Objectives:

By the end of the program, participants will be able to:
  • employ new approaches for leveraging genomic tools to validate targets, streamline clinical trials, decrease late development attrition, and identify patient groups in the marketplace.
  • apply program concepts to inform decisions about R&D priorities and directions, the evaluation of internal and external opportunities, and strategic thinking. 

Program topic areas include:

  • Applications of genetics in common and rare diseases
  • Discovery and validation of new targets
  • Moving from genes to function and phenotypes
  • Identifying causal biomarkers for clinical development
  • De-risking development by predicting potential adverse effects
  • Patient segmentation to streamline clinical trials
  • Strategic approach to companion diagnostics
  • Regulatory implications of genetics-informed development
  • Implications for increased use of genetics for patient-centric R&D
  • Future state: new technologies and approaches


Program faculty are preeminent experts in genomics and drug discovery and development, drawn from industry and academia. 

Stanley Shaw, MD, PhD, Faculty Chair 
Associate Dean for Executive Education, Harvard Medical School 

George M. Church, PhD
Professor of Genetics, Harvard Medical School; Professor of Health Sciences and Technology, Harvard and MIT

Frederick Dewey, MD
Senior Director and Head of Cardiometabolic, Skeletal Diseases, and Large Scale Data Mining, Regeneron Genetics Center

Sally John, PhD 
Vice President, Translational Biology, Biogen Idec 

Sekar Kathiresan, MD 
Director, Center for Genomic Medicine, Massachusetts General Hospital; Director, Cardiovascular Disease Initiative, Broad Institute; Associate Professor of Medicine, Harvard Medical School 

Jeffrey D. Marrazzo, MBA, MPA
CEO, Spark Therapeutics

Michelle Penny, PhD
Senior Director, Head of Computational Biology and Genomics, Biogen

Robert Plenge, MD, PhD 
Vice President, Translational Development, Research & Early Development, Celgene

Paula Sandler, PhD
Independent Consultant, Regulatory Affairs and Former Vice President, Regulatory Affairs, Biogen 

Ramnik Xavier, MD, PhD 
Chief, Gastroenterology Unit, Massachusetts General Hospital; Institute Member, Co-Director of the Infectious Disease and Microbiome Program, Broad Institute; Kurt Isselbacher Professor of Medicine, Harvard Medical School

David Williams, MD
President, Dana-Farber, Boston Children's Cancer and Blood Disorders Center; Senior Vice President and Chief Scientific Officer, Boston Children's Hospital; Chief, Hematology/Oncology, Boston Children's Hospital
Please complete the form below to access the complete program agenda, including program sessions and speakers. 


or 617-432-5212